Cullinan Therapeutics (CGEM) Institutional Ownership

During the previous two years, 123 institutional investors and hedge funds held shares of Cullinan Therapeutics. The most heavily invested institutionals were Deerfield Management Company L.P. Series C ($41.16M), State Street Corp ($39.13M), CHI Advisors LLC ($36.74M), Vanguard Group Inc. ($35.76M), BVF Inc. IL ($32.70M), Blue Owl Capital Holdings LP ($28.88M), and RTW Investments LP ($28.56M).Learn more on CGEM's institutional investors.

86.31% of Cullinan Therapeutics stock is owned by institutional investors. Learn more on CGEM's institutional investor holdings.

Of the 109 institutional investors that purchased Cullinan Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Braidwell LP ($2.91M), Deerfield Management Company L.P. Series C ($2.24M), Franklin Resources Inc. ($1.94M), Lynx1 Capital Management LP ($1.22M), Marshall Wace LLP ($1.14M), Boxer Capital Management LLC ($907.90K), and Patient Square Capital LP ($878.90K).

Institutional investors have bought a total of 20,810,283 shares in the last 24 months. This purchase volume represents approximately $289.00M in transactions.

Of the 40 institutional investors that sold Cullinan Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: BVF Inc. IL ($4.31M), American International Group Inc. ($1.23M), Blue Owl Capital Holdings LP ($875.67K), EcoR1 Capital LLC ($788.63K), Braidwell LP ($668K), Marshall Wace LLP ($402.07K), and Adage Capital Partners GP L.L.C. ($325.44K).

Institutional investors have sold a total of 10,555,143 shares in the last 24 months. This volume of shares sold represents approximately $131.54M in transactions.